You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD30-Positive Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Study of People With CD30 Positive Lymphoma in China

Not yet recruiting
  • Lymphoma
    • (no location specified)
    Aug 17, 2022

    Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

    Recruiting
    • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
    • Classical Hodgkin Lymphoma
    • CD30.CAR-EBVST cells
    • Houston, Texas
    • +1 more
    Jul 20, 2022

    Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

    Active, not recruiting
    • Peripheral T Cell Lymphoma
    • Pediatric Hodgkin Lymphoma
    • Brentuximab Vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Oct 11, 2022

    Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

    Active, not recruiting
    • Anaplastic Large Cell Lymphoma
    • +4 more
    • Duarte, California
    • +3 more
    Jul 21, 2022

    Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

    Not yet recruiting
    • Pediatric Cancer
    • +11 more
    • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
    • Milwaukee, Wisconsin
      Children's Wisconsin
    Sep 14, 2022

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

    Withdrawn
    • T Cell Lymphoma
    • Brentuximab Vedotin
    • Kansas City, Kansas
      The University of Kansas Cancer Center, Westwood Campus
    Feb 1, 2023

    Brentuximab Vedotin Intravenous Infusion "Untreated

    Active, not recruiting
    • Untreated CD30-Positive Hodgkin's Lymphoma
    • Brentuximab vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Mar 24, 2022

    T-Cell Lymphoma Trial (Brentuximab vedotin)

    Not yet recruiting
    • T-Cell Lymphoma
    • Brentuximab vedotin
    • (no location specified)
    Jun 30, 2022

    Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

    Not yet recruiting
    • Lymphoma
    • Brentuximab Vedotin
    • +3 more
    • Beijing, China
    • +15 more
    Jan 4, 2023

    Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

    Recruiting
    • Recurrent Anaplastic Large Cell Lymphoma
    • +9 more
    • Anti-CD30/CD16A Monoclonal Antibody AFM13
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

    Not yet recruiting
    • T-Cell Lymphoma
    • (no location specified)
    Jul 22, 2022

    Brentuximab Vedotin in Pediatric Hodgkin Lymphoma

    Not yet recruiting
    • Hodgkin Lymphoma
    • Brentuximab Vedotin
    • (no location specified)
    Jul 28, 2022

    NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)

    Not yet recruiting
    • NK/T Cell Lymphoma Nos
    • Brentuximab Vedotin in Combination with Tislelizumab
    • (no location specified)
    Apr 6, 2022

    Brentuximab Vedotin in Adults With CD30-positive Lymphoma

    Recruiting
    • Lymphoma
    • No Intervention
    • Hefei, Anhui, China
    • +25 more
    Jul 14, 2022

    Lymphatic Diseases Trial in Italy (Brentuximab Vedotin)

    Completed
    • Lymphatic Diseases
    • Brentuximab Vedotin
    • Bologna, Italy
    • +3 more
    Mar 21, 2022

    Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

    Not yet recruiting
    • Hodgkin Lymphoma
    • +2 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center
    Oct 13, 2023

    Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

    Not yet recruiting
    • Classical Hodgkin Lymphoma
    • Non-Hodgkin Lymphoma
    • GEN3017
    • (no location specified)
    Aug 25, 2023

    CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive DLBCL, CD30-Positive Gray Zone Lymphoma Trial in

    Completed
    Has Results
    • CD30 Positive Primary Mediastinal Large B-cell Lymphoma
    • +2 more
    • brentuximab vedotin
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Dec 14, 2020

    Lymphoma, T-Cell, Cutaneous Trial in New York (AFM13)

    Completed
    • Lymphoma, T-Cell, Cutaneous
    • New York, New York
      Center for Lymphoid Malignancies
    Jul 14, 2020

    Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

    Recruiting
    • Lymphoma
    • CD70-targeting CAR-T cells
    • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
      China
    Jul 9, 2023

    Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

    Recruiting
    • Lymphoma
    • +7 more
    • ATLCAR.CD30 cells
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Dec 2, 2022

    Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic Trial in China (Brentuximab Vedotin)

    Completed
    Has Results
    • Hodgkin Disease
    • Lymphoma, Large-Cell, Anaplastic
    • Brentuximab Vedotin
    • Beijing, Beijing, China
    • +6 more
    Feb 3, 2021

    Lymphoma, Relapse/Recurrence Trial in Wuhan, Nanchang (CD30 CAR-T, Camrelizumab)

    Recruiting
    • Lymphoma
    • Relapse/Recurrence
    • Wuhan, Hubei, China
    • +1 more
    Apr 8, 2022

    Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning)

    Active, not recruiting
    • Hodgkin Lymphoma
    • Brentuximab Vedotin
    • +2 more
    • Valhalla, New York
      New York Medical College
    Oct 24, 2022